{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-024877","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.734431+00:00","generated_at":"2026-06-20T00:05:23.721536+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Viridian Therapeutics appoints Scott Myers as President and CEO, succeeding Jonathan Violin","bullets":["Scott Myers, former CEO of AMAG Pharmaceuticals, appointed President & CEO and Class III Director effective Feb 6, 2023.","Founding CEO Jonathan Violin steps down; receives 18-month salary severance, 12-month accelerated option vesting, and consulting role.","Myers granted inducement award of 1,000,000 stock options and 250,000 RSUs, vesting over 4 years with first cliff at 12 months.","Company references positive topline data from Phase 1/2 trial of VRDN-001 for thyroid eye disease (previously filed presentation)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-024877","json":"https://secwatch.observer/filing/0001193125-23-024877.json","markdown":"https://secwatch.observer/filing/0001193125-23-024877.md","text":"https://secwatch.observer/filing/0001193125-23-024877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/d406212d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:05:23.721536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c22349114","claim":"Scott Myers was appointed as President and Chief Executive Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"appointment of Scott Myers as the Company’s President and Chief Executive Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9b1629ad65","claim":"Scott Myers was appointed as Class III Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"Mr. Myers was also appointed as a Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}